Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.43 |
| ▸ | ITGAV | P06756 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.43 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.43 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496596 | 0.83 | KDM4C (0.54) | KDM4CKMT2ABDKRB1DHODH | |
| SCHEMBL5756198 | 0.82 | KDR (0.61) | F10ABCB1BDKRB1 | |
| Hydrochloric Acid SCHEMBL6890222 | 0.80 | F10 (0.54) | F10ABCB1BDKRB1 | |
| SCHEMBL6780369 | 0.80 | ABCB1 (0.54) | F10ABCB1BDKRB1 | |
| SCHEMBL5760386 | 0.80 | F10 (0.72) | F10ABCB1KMT2ABDKRB1 | |
| Hydrochloric Acid SCHEMBL6773419 | 0.79 | F10 (0.55) | F10ABCB1ITGB3ITGB1ITGAV | |
| Hydrochloric Acid SCHEMBL6774426 | 0.79 | F10 (0.53) | F10ABCB1BDKRB1 | |
| Hydrochloric Acid SCHEMBL6774852 | 0.79 | ABCB1 (0.53) | F10ABCB1BDKRB1 | |
| SCHEMBL5758848 | 0.78 | F10 (0.53) | F10CYP2C9 | |
| SCHEMBL5758802 | 0.77 | ABCB1 (0.51) | F10ABCB1BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140881-B1 | ANTITHROMBOTIC AMIDES | LILLY CO ELI (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6780878-B2 | ANTICOAGULANTS; CARDIOVASACULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-24 | — | — | US | disclosed |
| US-6716839-B2 | INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6716855-B2 | INHIBITOR OF FACTOR XA; N1-(BENZOYL)-N2-(1-(4-PYRIDYL)PIPERIDIN-4-YL-METHYL)-1,2-BENZENDIAMINE HIGH BIOAVAILABILITY | ELI LILLY AND COMPANY | 2004-04-06 | — | — | US | disclosed |
| US-6710057-B2 | INHIBITORS OF FACTOR XA, AS ANTICOAGULANTS FOR PROPHYLAXIS AND TREATMENT OF THROMBOEMBOLIC DISORDERS | ELI LILLY AND COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-6689780-B1 | PYRIDINE DERIVATIVES | ELI LILLY AND COMPANY | 2004-02-10 | — | — | US | disclosed |
| US-20030212069-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-11-13 | — | — | US | disclosed |
| US-20030199504-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030199505-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-23 | — | — | US | disclosed |
| US-20030191153-A1 | Antithrombotic amides | ARGENTUM PHARMACEUTICALS LLC | 2003-10-09 | — | — | US | disclosed |
| US-6610704-B1 | Inhibit factor Xa | ELI LILLY AND COMPANY | 2003-08-26 | — | — | US | disclosed |
| EP-1140905-B1 | HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA | LILLY CO ELI (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1140905-A1 | HETEROAROMATIC AMIDES AS INHIBITOR OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039117-A1 | HETEROROAROMATIC AMIDES AS INHIBITOR OF FACTOR Xa | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191153-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | F10 13/4885ABCB1 1732/4885KDM4C 3861/4885 |
| US-20030199504-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | F10 13/4885ABCB1 1732/4885KDM4C 3861/4885 |
| US-20030212069-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | F10 13/4885ABCB1 1732/4885KDM4C 3861/4885 |
| US-20030199505-A1 | Antithrombotic amides | F11, TFPI, SERPINC1 | F10 13/4885ABCB1 1732/4885KDM4C 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.